Course Director

Stephen V. Liu, MD
Stephen V. Liu, MD

Georgetown University
Lombardi Comprehensive Cancer Center
Washington, DC, USA


Nicolas Girard
Nicolas Girard, MD

Institute Curie
Paris, France

Barbara Melosky
Barbara Melosky, MD, FRCP(C)

University of British Columbia
British Columbia Cancer Agency
Vancouver, British Columbia, Canada

Accredited by

Oakstone Publishing

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2019-Jun-28
Expiration Date:2020-Jun-27
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of Charge

Funding Disclosure

This activity is supported by an educational grant from AstraZeneca.

Activity Description and Educational Objectives

In this activity, experts in lung cancer discuss the latest data regarding treatment for EGFR-mutant non–small-cell lung cancer.

Upon completion of this activity, participants should be better able to:
  • Analyse the efficacy and safety data from clinical trials evaluating first-line EGFR-targeted therapies for non–small-cell lung cancer (NSCLC)
  • Re-evaluate current practices for managing advanced EGFR-mutant NSCLC in light of emerging evidence
  • Apply clinical evidence on the management of advanced EGFR-mutant NSCLC to patient care scenarios

Target Audience

This activity has been designed to meet the educational needs of cancer specialists and other clinicians involved in non–small-cell lung cancer.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

Stephen V. Liu, MD
Associate Professor of Medicine
Georgetown University
Lombardi Comprehensive Cancer Center
Washington, DC, USA

Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Plc; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Pfizer Inc.; Taiho Pharmaceutical Co., Ltd; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AstraZeneca Plc; Bayer AG; Blueprint Medicines Corporation.; Bristol-Myers Squibb Company; Clovis Oncology, Inc.; Corvus Pharmaceuticals; Esanex, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Ignyta, Inc.; Eli Lilly and Company; Lycera Corp.; Merck & Co., Inc.; Molecular Partners; MSD; OncoMed Pharmaceuticals, Inc.; Pfizer Inc.; Rain Therapeutics Inc.; and Threshold Pharmaceuticals.
Advisory Board for Apollomics, Inc.; Ariad Pharmaceuticals, Inc.; AstraZeneca Plc; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; G1 Therapeutics, Inc.; Genentech, Inc.; Heron Therapeutics, Inc.; Ignyta, Inc.; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.


Nicolas Girard, MD
Institute Curie
Paris, France

Nicolas Girard, MD, has no financial interest/relationship or affiliations in relation to this activity.

Barbara Melosky, MD, FRCP(C)
Clinical Professor, University of British Columbia
Medical Oncologist, British Columbia Cancer Agency
Vancouver, British Columbia, Canada

Barbara Melosky, MD, FRCP(C), has a financial interest/relationship or affiliation in the form of:
Advisory Board for AstraZeneca Canada Inc.; Biogen Canada Inc.; F. Hoffmann-La Roche Ltd; and Pfizer Canada Inc.
Honoraria from AstraZeneca Canada Inc.; Biogen Canada Inc.; F. Hoffmann-La Roche Ltd; and Pfizer Canada Inc.

PeerVoice Medical Director

Kathy D. Day has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and PeerVoice. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (

This CME activity is jointly provided by Oakstone Publishing and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: 28 June 2019 - 27 June 2020
Time to Complete: 30 minutes


The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

For technical assistance, please contact us.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.